CYP2C9-catalyzed metabolism of S-warfarin to 7-hydroxywarfarin in vivo and in vitro in chimeric mice with humanized liver

Drug Metabolism and Disposition

Volumn 36, Issue 12, 2008, Pages 2429-2433

  Inoue, Tae ^a,b   Nitta, Kayoko ^a   Sugihara, Kazumi ^a   Horie, Toru ^b   Kitamura, Shigeyuki ^a,c   Ohta, Shigeru ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b PhoenixBio USA Corporation   (Japan)

^c NIHON PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYWARFARIN; CYTOCHROME P450 2C9; DRUG METABOLITE; SULFAPHENAZOLE; UNCLASSIFIED DRUG; UROKINASE; WARFARIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHIMERIC MOUSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; ENZYME ACTIVITY; HEPATOCYTE TRANSPLANTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIVER MICROSOME; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SINGLE DRUG DOSE; TRANSGENIC MOUSE;

ADOLESCENT; ANIMALS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CHILD; CHILD, PRESCHOOL; HEPATOCYTES; HUMANS; LIVER; MALE; MICE; MICE, SCID; MICROSOMES, LIVER; SULFAPHENAZOLE; TRANSPLANTATION CHIMERA; WARFARIN;

MUS;

EID: 57349175932     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.022830     Document Type: Article

References (28)

1. Corchero J, Granvil CP, Akiyama TE, Hayhurst GP, Pimprale S, Feigenbaum L, Idle JR, and Gonzalez FJ (2001) The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4α on the disposition of debrisoquine in the mouse. Mol Pharmacol 60:1260-1267.
2. Dandri M, Burda MR, Török E, Pollok JM, Iwanska A, Sommer G, Rogiers X, Rogler CE, Gupta S, Will H, et al. (2001) Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 33:981-988.
3. Greenblatt DJ and von Moltke LL (2005) Interaction of warfarin with drugs, natural substances and foods. J Clin Pharmacol 45:127-132.
4. Kaminsky LS, de Morais SM, Faletto MB, Dunbar DA, and Goldstein JA (1993) Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol Pharmacol 43:234-239.
5. Kaminsky LS, Guengerich FP, Dannan GA, and Aust SD (1983) Comparisons of warfarin metabolism by liver microsomes of rats treated with a series of polybrominated biphenyl congeners and by the component-purified cytochrome P-450 isozymes. Arch Biochem Biophys 225:398-404.
6. Kaminsky LS and Zhang ZY (1997) Human P450 metabolism of warfarin. Pharmacol Ther 73:67-74.
7. Katoh M, Matsui T, Nakajima M, Tateno C, Kataoka M, Soeno Y, Horie T, Iwasaki K, Yoshizato K, and Yokoi T (2004) Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab Dispos 32:1402-1410.
8. Katoh M, Matsui T, Okumura H, Nakajima M, Nishimura M, Naito S, Tateno C, Yoshizato K, and Yokoi T (2005a) Expression of human phase II enzymes in chimeric mice with humanized liver. Drug Metab Dispos 33:1333-1340.
9. Katoh M, Matsui T, Nakajima M, Tateno C, Soeno Y, Horie T, Iwasaki K, Yoshizato K, and Yokoi T (2005b) In vivo induction of human cytochrome P450 enzymes expressed in chimeric mice with humanized liver. Drug Metab Dispos 33:754-763.
10. 1- methylnicotinamide in vivo and in vitro in chimeric mice with humanized liver. Drug Metab Dispos 36:1202-1205, 2008.
11. Lang D and Böcker R (1995) Highly sensitive and specific high-performance liquid chromatographic analysis of 7-hydroxywarfarin, a marker for human cytochrome P-4502C9 activity. J Chromatogr B Biomed Appl 672:305-309.
12. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
13. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, Addison WR, Fischer KP, Churchill TA, Lakey JR, et al. (2001) Hepatitis C virus replication in mice with chimeric human livers. Nat Med 7:927-933.
14. Miksys SL, Cheung C, Gonzalez FJ, and Tyndale RF (2005) Human CYP2D6 and mouse CYP2DS: organ distribution in a humanized mouse model. Drug Metab Dispos 33:1495-1502.
15. Nakajima M, Tane K, Nakamura S, Shimada N, Yamazaki H, and Yokoi T (2002) Evaluation of approach to predict the contribution of multiple cytochrome P450s in drug metabolism using relative activity factor: effects of the differences in expression levels of NADP-cytochrome P450 reductase and cytochrome b5 in the expression system and the differences in the marker activities. J Pharm Sci 91:952-963.
16. Nishimura M, Yokoi T, Tateno C, Kataoka M, Takahashi E, Horie T, Yoshizato K, and Naito S (2005) Induction of human CYP1A2 and CYP3A4 in primary culture of hepatocytes from chimeric mice with humanized liver. Drug Metab Pharmacokinet 20:121-126.
17. O'Reilly RA (1974) Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther 16:348-354.
18. Park BK (1988) Warfarin: metabolism and mode of action. Biochem Pharmacol 37:19-27.
19. Rettie AE, Eddy AC, Heimark LD, Gibaldi M, and Trager WF (1989) Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab Dispos 17:265-270.
20. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, and Trager WF (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 5:54-59.
21. Robertson GR, Field J, Goodwin B, Bierach S, Tran M, Lehnert A, and Liddle C (2003) Transgenic mouse models of human CYP3A4 gene regulation. Mol Pharmacol 64:42-50.
22. Rodríguez-Antona C, Donato MT, Boobis A, Edwards RJ, Watts PS, Castell JV, and Gómez-Lechón MJ (2002) Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 32:505-520.
23. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, Tachibana A, Soeno Y, Asahina K, Hino H, et al. (2004) Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165:901-912.
24. Toon S, Low LK, Gibaldi M, Trager WF, O'Reilly, Motley CH, and Goulart DA (1986) The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin Pharmacol Ther 39:15-24.
25. Wienkers LC, Wurden CJ, Storch E, Kunze KL, Rettie AE, and Trager WF (1996) Formation of (R)-8-hydroxywarfarin in human liver microsomes: a new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab Dispos 24:610-614.
26. Yamazaki H and Shimada T (1997) Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. Biochem Pharmacol 54:1195-1203.
27. Zhang W, Purchio AF, Chen K, Wu J, Lu L, Coffee R, Contag PR, and West DB (2003) A transgenic mouse model with a luciferase reporter for studying in vivo transcriptional regulation of the human CYP3A4 gene. Drug Metab Dispos 31:1054-1064.
28. Zhu X and Shin WG (2005) Gender differences in pharmacokinetics of oral warfarin in rats. Biopharm Drug Dispos 26:147-150.